News
06-06-2011, 10:50 PM
Teva Pharmaceutical Industries Ltd. announced today that lipegfilgrastim achieved its primary endpoint of reducing the duration of severe neutropenia in a Phase III study designed to evaluate the efficacy and safety of lipegfilgrastim (XM22) compared to pegfilgrastim (Amgen's Neulasta™).
More... (http://www.news-medical.net/news/20110607/Tevas-lipegfilgrastim-pegfilgrastim-comparative-Phase-III-study-in-breast-cancer-meets-primary-endpoint.aspx)
More... (http://www.news-medical.net/news/20110607/Tevas-lipegfilgrastim-pegfilgrastim-comparative-Phase-III-study-in-breast-cancer-meets-primary-endpoint.aspx)